Company profile · federal money
Orpro Therapeutics Inc
Orpro Therapeutics Inc received $509.0K in federal awards in FY2025. Largest customer: Department of Health and Human Services ($509.0K).
- FY2025 federal obligations
- $509.0K
Largest customers: Department of Health and Human Services $509.0K
Data through 2026-09-30; source: USAspending.gov.
Gathering everything on record…
From public government records, which may contain errors. Check the official source before relying on a number. Not financial, legal or investment advice. Terms · About the data
SBIR & STTR awards
5 small-business research awards (1 Phase II) worth $2.64M, 2012–2025.
- Engineered Monothiol Thioredoxin for Treatment of Radiation Induced Lung Injury Department of Health and Human Services · STTR Phase I · $509.0K · 2025
- Development of modified human thioredoxin as an inhaled biologic therapeutic for cystic fibrosis Department of Health and Human Services · SBIR Phase II · $1.50M · 2018
- Mucoadhesive drug conjugates for controlled-release inhalation delivery Department of Health and Human Services · SBIR Phase I · $228.4K · 2018
- Development of modified human thioredoxin as an inhaled biologic therapeutic for cystic fibrosis Department of Health and Human Services · SBIR Phase I · $224.5K · 2018
- Development of human thioredoxin as a mucolytic therapy for Cystic Fibrosis Department of Health and Human Services · SBIR Phase I · $183.1K · 2012
All of its SBIR & STTR awards · SBA's SBIR.gov data